

[REDACTED]

[REDACTED]

*CONFIDENTIAL COMMERCIAL COMMUNICATION*

August 18, 2015

*Via Email: [douglas.stearn@fda.hhs.gov](mailto:douglas.stearn@fda.hhs.gov); [domenic.veneziano@fda.hhs.gov](mailto:domenic.veneziano@fda.hhs.gov); [michael.k.dean@cbp.dhs.gov](mailto:michael.k.dean@cbp.dhs.gov)*

Douglas Stearn  
Director  
Office of Enforcement and Import Operations  
U.S. Food and Drug Administration  
12420 Parklawn Drive  
Rockville, MD 20857

*Re: Request for Delivery of Imported Sodium Thiopental to Destination*

Dear Mr. Stearn,

We represent the Arizona Department of Corrections. Please see attached authorization letter. On August 5, 2015 the Customs Service Port at the Phoenix International Airport detained our client's shipment of thiopental sodium – entry number [REDACTED]

According to the Detention Notice, CBP is detaining the goods at the request of FDA. Therefore, we request that FDA instruct CBP to lift the detention and permit the goods to proceed to destination under the importer's basic importation bond as is ordinary in the course of commercial import transactions.

The Arizona Department of Corrections needs to receive the goods at destination to complete the transaction for the goods. To that end, the Director of the Arizona Department of Corrections has declared in writing that upon receipt of the goods at destination it will not use the product unless and until FDA's pending detention of the good is resolved. *See* attached.

\* \* \*

If you have any questions regarding the foregoing, please feel free to contact me or my Senior Associate, [REDACTED] by phone [REDACTED] or email at [REDACTED]

Sincerely,  
[REDACTED]

# Arizona Department of Corrections



DOUGLAS A. DUCEY  
GOVERNOR

1801 WEST JEFFERSON  
PHOENIX, ARIZONA 85007  
(602) 542-5497  
www.azcorrections.gov



CHARLES L. RYAN  
DIRECTOR

July 24, 2015

To Whom It May Concern:

RE: FDA, DEA and U.S. CBP matters

Please be advised we, Arizona Department of Corrections, have authorized the [REDACTED] to engage the U.S. Food and Drug Administration (FDA), the Drug Enforcement Agency, and the Bureau of Customs and Border Protection (CBP) respecting all issues related to the manufacture, distribution, exportation, and importation of FDA-regulated products.

In order to assist us in our matters, we authorize you to discuss our FDA, DEA and CBP related issues, filings, and records with [REDACTED] and the other attorneys at the firm, [REDACTED]

[REDACTED] or their paralegals. [REDACTED] The Firm's telephone number is [REDACTED] if you have any questions regarding this authorization, please do not hesitate to contact me at [REDACTED]

Sincerely,

[REDACTED]